title: [Intact whole bioactive parathormone: problems arising from comparing different methods].
abstract: BACKGROUND
  Parathyroid hormone (PTH) has important applications in the nephrological clinical practice. Because assays of Intact PTH (I-PTH) are liable to interferences by N-truncated fragments, a novel method for whole-(1-84) PTH has been proposed. This study is aimed at comparing the latter with some of the previous I-PTH assays. For each method the results are referred to pertinent markers of mineral metabolism.
  
  
  METHODS
  We enrolled 171 subjects, including 56 healthy controls (C), 65 calcium stone- formers (CaSF), 40 haemodialysis patients (HD), 10 with primary hyperparathyroidism (PHP). On blood samples we measured: I-PTH by four methods (N-Tact, Advantage, Elecsys, Scantibodies), whole-(1-84) PTH, defined as CAP (Cyclase Activating PTH), total and ionised calcium, phosphate, vitamin D, osteocalcin and Crosslaps. The difference between I-PTH and CAP Scantibodies is defined as CIP (Cyclase Inhibiting PTH).
  
  
  RESULTS
  Despite relating to each other (r>0.97) PTH values varied remarkably among methods. For all methods, the reference intervals differed from those provided by the producer. Assuming these new ranges, 10 CaSF had over-range values not always associated with abnormalities of mineral metabolism. One of the PHP patients was normal for I-PTH with 2/4 methods. In HD the differences among methods were even greater, there were inverse (p<0.05) and direct (p<0.001) relationships with ionised calcium and osteocalcin-crosslaps, respectively. The CAP/CIP ratio was lower in low bone turnover patients, but the two subgroups widely overlapped.
  
  
  CONCLUSIONS
  This study indicates that the reliability of I-PTH assays is still unsatisfactory, and none of the four methods emerged as the best. Assay for CAP only improves diagnostic efficiency, whereas the CAP/CIP ratio does not exhibit powerful discriminating capacity. Our suggestion is that each Centre should establish its own reference ranges. PTH assay should always be coupled with measurements of other markers of mineral metabolism as well as renal function.
mesh_terms: D000328:Adult; D000368:Aged; D016477:Artifacts; D002118:Calcium / Q000097:blood; D003094:Collagen / Q000097:blood; D003429:Cross Reactions; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood; D015592:Immunoradiometric Assay; D007669:Kidney Calculi / Q000097:blood; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood; D010710:Phosphates / Q000097:blood; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic; D006435:Renal Dialysis; D015203:Reproducibility of Results; D014511:Uremia / Q000097:blood / Q000628:therapy; D014807:Vitamin D / Q000097:blood
chemical_list: D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010710:Phosphates; D011933:Reagent Kits, Diagnostic; C110762:glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine; D015675:Osteocalcin; D014807:Vitamin D; D003094:Collagen; D002118:Calcium
vernacular_title: Paratormone intatto intero bioattivo: le problematiche emergenti dal confronto.